Allied Biotech Corporation (立弘生技), a specialized global biotechnology supplier with over 20 years of deep cultivation in carotenoid chemistry, hosted its pre-IPO performance presentation on May 22, 2026. The company is scheduled to formally debut on the mainboard of the Taipei Exchange (TPEx) in late June 2026, with the tentative IPO underwriting price set at NT$20 per share.

• Market Capitalization and Technical Moats: Allied Biotech stands as a premier global manufacturer of synthetic carotenoids and is one of the rare industrial suppliers in Asia capable of mass-producing an all-inclusive product portfolio, including $beta$-carotene, apocarotenal, canthaxanthin, lycopene, and lutein.
• The Dual-Engine Core Capability: Chairman Yang Cheng-li noted that Allied Biotech's industrial moat is driven by its dual competencies in complex chemical synthesis and advanced formulation technologies. Utilizing high-precision chemical synthesis, the company elevates the purity of its lycopene crystals to over 95%, significantly outperforming the industry baseline average of approximately 70%. Currently, Allied Biotech’s proprietary commercial brands—Altratene®, Lycotene®, and Lutene®—are exported to more than 60 countries, successfully penetrating the strict supply chains of the world's top three food and beverage multinationals and the top five global flavor and fragrance conglomerates.
• Macro Regulatory Tailwinds: The global food tech landscape is experiencing a structural shift as natural and nature-identical pigments replace synthetic azo dyes due to tightening food safety regulations. In 2025, under the federal "Make America Healthy Again" policy initiative, the US FDA announced an aggressive regulatory timeline targeting the complete phase-out of six artificial food colorings (including Red 40, Yellow 5, and Yellow 6) from human food supplies by the end of 2026. Concurrently, the California Food Safety Act is set to ban these synthetic dyes in public school cafeterias starting in late 2027.
• Commercial Backlog: Management clarified that Allied Biotech's extensive carotenoid color matrix, which completely spans the yellow-to-red spectrum, serves as an immediate, turn-key replacement solution for global food manufacturers. Multiple tier-one US food brands are currently running final sample validation and stability testing workflows with Allied Biotech's formulations. The completion of these institutional certifications and subsequent mass-volume shipments are projected to serve as the primary catalyst driving top-line revenue acceleration over the coming fiscal periods.

Resource:立弘6月下旬上櫃 每股承銷價暫定20元